/PRNewswire/ VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel.
A number of awards of distinction were presented during The VEINS (Venous Endovascular INterventional Strategies) 2022 Conference Oct. 30-31, and the VIVA22, Oct. 31-Nov. 3 in Las Vegas, NV, recognizing specialists in endovascular medicine.
A hospital-wide quality improvement initiative including adoption of institutional guidelines, new prescribing prompts and a teaching curriculum was associated with a reduction in the use and duration of triple therapy after PCI, data show.The American College of Cardiology expert consensus pathway recommends against the routine use of triple therapy after PCI, Eric A. Secemsky, MD, MSc, RPVI,